Trial · NCT00696878
Outcomes69
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 69
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Clinically Relevant Immunogenicity | Pre-dose (Stimulation Day 1) and up to approximately 40 days post dose in each treatment cycle | Participants who received corifollitropin alfa and had a post dose sample for anti-corifollitropin alfa antibody testing | percentage of participants | NUMBER |
| PRIMARY | Local Tolerance at Injection Site: Number of Participants With no Event of Itching and With Mild, Moderate and Severe Itching in Any of 3 Treatment Cycles | 30 minutes post dose in each treatment cycle | Participants who received corifollitropin alfa | participants | NUMBER |
| PRIMARY | Local Tolerance at Injection Site: Number of Participants With no Event of Pain and With Mild, Moderate and Severe Pain in Any of 3 Treatment Cycles | 30 minutes post dose in each treatment cycle | Participants who received corifollitropin alfa | participants | NUMBER |
| PRIMARY | Local Tolerance at Injection Site: Number of Participants With no Event of Redness and With Mild, Moderate and Severe Redness in Any of 3 Treatment Cycles | 30 minutes post dose in each treatment cycle | Participants who received corifollitropin alfa | participants | NUMBER |
| PRIMARY | Local Tolerance at Injection Site: Number of Participants With no Event of Swelling and With Mild, Moderate and Severe Swelling in Any of 3 Treatment Cycles | 30 minutes post dose in each treatment cycle | Participants who received corifollitropin alfa | participants | NUMBER |
| PRIMARY | Local Tolerance at Injection Site Overall Summary: Number of Participants With no Local Tolerance Event (Itching, Pain, Redness or Swelling) and With a Mild, Moderate and Severe Local Tolerance Event in Any of 3 Treatment Cycles | 30 minutes post dose in each treatment cycle | Participants who received corifollitropin alfa | participants | NUMBER |
| PRIMARY | Number of Participants With AEs | Up to approximately 26 months after first dose of corifollitropin alfa | Participants who received corifollitropin alfa | participants | NUMBER |
| PRIMARY | Number of Participants With Serious AEs (SAEs) | Up to approximately 26 months after first dose of corifollitropin alfa | Participants who received corifollitropin alfa | participants | NUMBER |
| PRIMARY | Number of Participants With Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS) | Up to approximately 1 month after oocyte pick-up (34-36 hours after [rec]hCG administration [approximately Stimulation Day 10]), within a treatment cycle | Participants who received corifollitropin alfa | participants | NUMBER |
| SECONDARY | Amount of (Rec)FSH Needed From Stimulation Day 8 Onwards to Reach the Criterion for Administration of (Rec)hCG | Stimulation Day 8 to day of (rec)hCG administration (approximately Stimulation Day 10), within a treatment cycle | Participants who received corifollitropin alfa and (rec)hCG | International Unit (IU) | MEDIAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 1 During Treatment Cycle 1 | Stimulation Day 1 in Treatment Cycle 1 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 1 in Treatment Cycle 1 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 1 During Treatment Cycle 2 | Stimulation Day 1 in Treatment Cycle 2 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 1 in Treatment Cycle 2 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 1 During Treatment Cycle 3 | Stimulation Day 1 in Treatment Cycle 3 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 1 in Treatment Cycle 3 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 5 or 6 During Treatment Cycle 1 | Stimulation Day 5 or 6 in Treatment Cycle 1 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 5 or 6 in Treatment Cycle 1 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 5 or 6 During Treatment Cycle 2 | Stimulation Day 5 or 6 in Treatment Cycle 2 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 5 or 6 in Treatment Cycle 2 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 5 or 6 During Treatment Cycle 3 | Stimulation Day 5 or 6 in Treatment Cycle 3 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 5 or 6 in Treatment Cycle 3 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 8 During Treatment Cycle 1 | Stimulation Day 8 in Treatment Cycle 1 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 8 in Treatment Cycle 1 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 8 During Treatment Cycle 2 | Stimulation Day 8 in Treatment Cycle 2 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 8 in Treatment Cycle 2 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Stimulation Day 8 During Treatment Cycle 3 | Stimulation Day 8 in Treatment Cycle 3 | Participants who received corifollitropin alfa and had data for assessment of follicles ≥11 mm on Stimulation Day 8 in Treatment Cycle 3 | follicles | MEAN |
| SECONDARY | Number of Follicles ≥11 mm, ≥15 mm and ≥17 mm Documented by Ultrasonography Performed in the Participant on Day of (Rec)hCG Administration During Treatment Cycle 1 | Day of (rec)hCG administration (approximately Stimulation Day 10) in Treatment Cycle 1 | Participants who received corifollitropin alfa and (rec)hCG, and had data for assessment of follicles ≥11 mm on day of (rec)hCG administration in Treatment Cycle 1 | follicles | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00696878/outcomes